---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-064547"
form_type: "8-K"
ticker: "BIOA"
cik: "0001709941"
company_name: "BioAge Labs, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T12:50:48.273235+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BioAge Labs Q1 net loss $12.9M; cash $335.1M; BGE-102 Phase 1 data expected 2H25

## Summary
- Net loss of $12.9M ($0.36 diluted EPS) vs $13.0M loss in Q1 2024; no revenue reported.
- R&D expenses $11.1M up from $9.3M YoY on IND-enabling work for BGE-102.
- G&A expenses $6.8M up from $3.5M YoY driven by stock-based compensation and D&O insurance.
- Cash, equivalents, and marketable securities $335.1M as of March 31, 2025; funds operations through 2029.
- Lead candidate BGE-102 (NLRP3 inhibitor) enters IND-enabling studies; initial Phase 1 data anticipated 2H25.

## SEC filing metadata
- accession: 0000950170-25-064547
- form_type: 8-K
- ticker: BIOA
- cik: 0001709941
- company_name: BioAge Labs, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1709941/000095017025064547/0000950170-25-064547-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1709941/000095017025064547/bioa-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-064547
- JSON: https://secwatch.observer/filing/0000950170-25-064547.json
- Plain text: https://secwatch.observer/filing/0000950170-25-064547.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.